This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Pediatric Atopic Dermatitis (AD) Internet Survey

This study is ongoing, but not recruiting participants.
Information provided by (Responsible Party):
Steven R. Feldman, Wake Forest University Health Sciences Identifier:
First received: June 28, 2011
Last updated: March 8, 2017
Last verified: March 2017
The purpose of this study is to evaluate whether participation in an Internet-based intervention helps improve atopic dermatitis treatment outcomes.

Condition Intervention
Atopic Dermatitis Behavioral: Weekly Internet survey Drug: Topical Triamcinolone

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Health Services Research
Official Title: Using an Internet Survey to Improve Adherence in Pediatric Atopic Dermatitis

Resource links provided by NLM:

Further study details as provided by Steven R. Feldman, Wake Forest University Health Sciences:

Primary Outcome Measures:
  • Adherence to topical triamcinolone [ Time Frame: 12 weeks ]

Secondary Outcome Measures:
  • Eczema Area Severity Index [ Time Frame: 12 weeks ]
  • Investigator's Global Assessment [ Time Frame: 12 weeks ]

Estimated Enrollment: 40
Study Start Date: June 2011
Estimated Study Completion Date: October 2017
Estimated Primary Completion Date: October 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Weekly Internet survey w medication
Weekly survey via email plus topical triamcinolone
Behavioral: Weekly Internet survey
Parents will complete a weekly online survey about medication use.
Drug: Topical Triamcinolone
Topical triamcinolone to all affected areas once daily
Active Comparator: Topical triamcinolone only
Standard of care
Drug: Topical Triamcinolone
Topical triamcinolone to all affected areas once daily


Ages Eligible for Study:   2 Years to 8 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Any child age 2 to 8 with a diagnosis of atopic dermatitis confirmed by a dermatologist, together with the child's parent/guardian. Written consent must be given by parent/guardian.

Exclusion Criteria:

  • Child is less than 2 or greater than 8 years of age.
  • Known allergy or sensitivity to topical triamcinolone in the child.
  • Inability to complete all study-related visits, or inability to complete the Internet survey due to inadequate Internet access.
  • Introduction of any other prescription medication, topical or systemic, for atopic dermatitis while participating in the study. Subjects who are on systemic anti-inflammatory treatments for atopic dermatitis must be on a stable dose for at least 3 months prior to enrollment.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01385527

United States, North Carolina
Wake Forest University Health Sciences Dermatology
Winston-Salem, North Carolina, United States, 27104
Sponsors and Collaborators
Wake Forest University
Principal Investigator: Steven R Feldman, MD, PhD Wake Forest University Health Sciences
  More Information

Responsible Party: Steven R. Feldman, Professor of Dermatology, Wake Forest University Health Sciences Identifier: NCT01385527     History of Changes
Other Study ID Numbers: 00016545
Study First Received: June 28, 2011
Last Updated: March 8, 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Additional relevant MeSH terms:
Dermatitis, Atopic
Skin Diseases
Skin Diseases, Genetic
Genetic Diseases, Inborn
Skin Diseases, Eczematous
Hypersensitivity, Immediate
Immune System Diseases
Triamcinolone hexacetonide
Triamcinolone Acetonide
Triamcinolone diacetate
Anti-Inflammatory Agents
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Immunosuppressive Agents
Immunologic Factors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action processed this record on August 22, 2017